Extended-release Naltrexone for Alcohol Dependence in Primary Care
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Naltrexone is an opioid antagonist with a high affinity for the mu opioid receptor. The
efficacy of extended-release naltrexone (Vivitrol) as a treatment for alcohol dependence has
been demonstrated in clinical trials, raising the prospect of integrating pharmacologic
treatment for alcohol dependence into general medical care settings. However, the feasibility
of implementing this United States Food and Drug Administration approved treatment in the
front-line settings in which it is most needed has not been demonstrated. This is an
open-label pilot feasibility study of implementing treatment with Vivitrol in primary care
medical clinics in a safety net hospital system affiliated with an urban academic center.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health